secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2021-08-02T23:59:59+00:00
Accession:  0001193125-21-232433
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics appoints Kristian Humer to board and audit committee
---------------------------------------------------------------------------

- Effective July 30, 2021, Kristian Humer appointed as Class II director and audit committee member.
- Humer previously Managing Director at Citigroup, now CFO/CBO of Viridian Therapeutics Inc.
- Initial option grant of 16,667 shares vesting over 36 months; annual retainer of $35,000 plus $7,500 for audit committee.
- No family relationships or arrangements with other directors/officers; standard indemnification agreement.
- Eligible for additional annual option of 8,333 shares vesting over 12 months, starting at 2022 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312521232433/0001193125-21-232433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312521232433/d207449d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-232433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer